Table 2.

Intrinsic properties across drug treatments

Incubation	IH sag, mV	Holding RMP, mV	Rm, MΩ	Significant time × drug effect on baseline I/O curve compared to baseline ACSF/VEH, 800 ms
ACSF
Baseline	10.5 ± 1.2	−71.4 ± 0.7	285.2 ± 34.4
VEH	8.0 ± 1.7a	−70.3 ± 0.9	249.3 ± 43.8
ACSF
Baseline	9.8 ± 1.1	−70.1 ± 0.2	223.7 ± 21.0	No difference, p = 0.9360
CRF	7.2 ± 1.1a	−69.5 ± 0.4	188.3 ± 20.5
ZD7288
Baseline	0.6 ± 0.4b	−71.5 ± 0.5	340.0 ± 36.4#	No difference, p = 0.5111
CRF	−0.5 ± 0.5b	−70.2 ± 0.7	332.0 ± 53.1#
Apamin
Baseline	8.6 ± 1.1	−73.1 ± 1.1	193.0 ± 13.0	Decrease, p = 0.0004
CRF	6.9 ± 0.9	−71.6 ± 0.7	180.5 ± 33.2
Rp-cAMPs
Baseline	5.9 ± 1.3	−68.7 ± 0.5	147.6 ± 22.5	No difference, p = 0.8730
CRF	3.9 ± 1.1	−69.5 ± 0.4	126 ± 14.2
PKI 14–22
Baseline	8.8 ± 1.2	−69.4 ± 0.5	181.4 ± 14.6	Increase, p < 0.0001
CRF	7.3 ± 1.4	−69.1 ± 0.5	190.6 ± 14.4
Chelrythrine
Baseline	10.3 ± 1.8	−70.1 ± 0.6	233.1 ± 35.8	No difference, p > 0.9999
CRF	10.9 ± 2.7	−68.7 ± 0.7	268.0 ± 42.9
Go 6983
Baseline	8.5 ± 1.2	−69.8 ± 0.6	261.4 ± 50.2	No difference, p = 0.2971
CRF	8.1 ± 1.6	−68.3 ± 1.0	298.3 ± 60.5

^aSidak's post hoc t test: baseline versus VEH/CRF.

^bSidak's post hoc test: drug incubation versus ACSF.